Samsung joins biosimilar race for Merck & Co.'s Keytruda blockbuster

On Wednesday, Samsung Bioepis announced that a randomised Phase I trial of its proposed biosimilar of Keytruda has gotten under way. The study will evaluate its candidate, dubbed SB27, in about 135 patients with stage II-IIIA non-small-cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy.